Tidal Investments LLC Purchases 4,244 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Tidal Investments LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,896 shares of the biopharmaceutical company’s stock after buying an additional 4,244 shares during the quarter. Tidal Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $27,371,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. California State Teachers Retirement System grew its holdings in Regeneron Pharmaceuticals by 63,274.2% during the 2nd quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company’s stock worth $60,934,625,000 after acquiring an additional 97,569,482 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $5,682,636,000. Dodge & Cox raised its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after purchasing an additional 45,513 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Regeneron Pharmaceuticals by 4.4% in the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after purchasing an additional 106,861 shares during the period. Finally, Nuveen LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s presentation at the Wells Fargo Healthcare Conference may provide investors with additional detail on its pipeline, commercial portfolio and strategy. However, the available report is a transcript and does not identify a new market-moving announcement. Wells Fargo conference transcript
• Neutral Sentiment: Recent fund commentary is mixed: Harbor Funds discussed the stock’s bullish potential, while American Century Investments reported selling its Regeneron position. These manager opinions may influence sentiment but do not change the company’s fundamentals. Harbor Funds commentary American Century fund sale
• Negative Sentiment: Several firms reiterated that investors who purchased REGN between August 1, 2025 and May 15, 2026 may seek lead-plaintiff status by September 14, 2026. The allegations focus on whether Regeneron adequately disclosed the protocol and risks of the Phase 3 fianlimab-Libtayo melanoma study, which ultimately failed; notices cite an earlier decline of roughly $102 per share from the class-period high. The repeated announcements increase litigation visibility and could keep a risk discount on the shares. Hagens Berman class-action notice Robbins Geller deadline notice
• Negative Sentiment: Analyst commentary also highlighted reasons to avoid REGN, including recent underperformance versus the broader market, adding to the cautious tone around the shares. Reasons to avoid REGN

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Royal Bank Of Canada lifted their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. HSBC cut their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $800.36.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $807.65 on Thursday. The company’s fifty day moving average price is $749.60 and its 200-day moving average price is $720.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $83.16 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 1.59 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the company earned $12.81 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.